CLB has been the topic of several other research reports. JPMorgan Chase & Co. restated a buy rating on shares of Core Laboratories NV in a report on Thursday, June 30th. KLR Group reiterated a buy rating and issued a $180.00 target price (up previously from $166.00) on shares of Core Laboratories NV in a report on Monday, June 13th. Zacks Investment Research downgraded Core Laboratories NV from a buy rating to a hold rating in a report on Monday, September 26th. Finally, Credit Suisse Group AG started coverage on Core Laboratories NV in a report on Thursday, September 1st. They issued a neutral rating and a $115.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $120.47.
Core Laboratories NV (NYSE:CLB) opened at 112.16 on Wednesday. The firm has a market capitalization of $4.95 billion, a PE ratio of 59.50 and a beta of 1.45. The stock’s 50 day moving average is $111.83 and its 200-day moving average is $117.60. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49.
Core Laboratories NV (NYSE:CLB) last posted its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.35. The firm had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. Core Laboratories NV had a return on equity of 344.55% and a net margin of 11.81%. The business’s revenue for the quarter was down 27.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. Equities analysts expect that Core Laboratories NV will post $1.55 earnings per share for the current year.
A number of large investors have recently made changes to their positions in CLB. Balentine LLC boosted its stake in shares of Core Laboratories NV by 44.3% in the second quarter. Balentine LLC now owns 893 shares of the company’s stock worth $111,000 after buying an additional 274 shares during the last quarter. MU Investments Co. Ltd. bought a new stake in shares of Core Laboratories NV during the second quarter worth about $115,000. Pinkerton Retirement Specialists LLC bought a new stake in shares of Core Laboratories NV during the second quarter worth about $127,000. Fifth Third Bancorp boosted its stake in shares of Core Laboratories NV by 15.3% in the second quarter. Fifth Third Bancorp now owns 1,166 shares of the company’s stock worth $144,000 after buying an additional 155 shares during the last quarter. Finally, AXA boosted its stake in shares of Core Laboratories NV by 94.2% in the second quarter. AXA now owns 1,400 shares of the company’s stock worth $173,000 after buying an additional 679 shares during the last quarter.
About Core Laboratories NV
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.